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Objective: Inhaled nitric oxide therapy causes selective and sustained
pulmonary vasodilation in patients with pulmonary hypertension; however,
attempts to discontinue inhaled nitric oxide therapy may be complicated by
abrupt life-threatening events. Dipyridamole, a cyclic guanosine mono-
phosphate–specific phosphodiesterase inhibitor, blocks the hydrolysis of
cyclic guanosine monophosphate in vascular smooth muscle cells. Methods:
We studied 23 consecutive children who were treated with inhaled nitric
oxide because of clinically significant pulmonary hypertension after surgery
for congenital heart disease. Inhaled nitric oxide therapy was withdrawn
before and after dipyridamole treatment of children in whom sustained
elevations of pulmonary artery pressure developed for over 30 minutes.
Results: In 7 of 23 children, inhaled nitric oxide withdrawal caused a 40%
increase in pulmonary artery pressure, a 17% decrease in systemic venous
oxygen saturation, and a 46% increase in the ratio of mean pulmonary
artery pressure to aortic pressure. Compared with children who had no
significant increase in pulmonary artery pressure, children who experi-
enced the development of prolonged pulmonary hypertension after inhaled
nitric oxide therapy withdrawal had higher mean pulmonary artery pres-
sure immediately before inhaled nitric oxide withdrawal (22 6 1 mm Hg
versus 27 6 2 mm Hg; p 5 0.04) and received inhaled nitric oxide for a
longer duration (2 6 1 days versus 4 6 1 days; p 5 0.01). Dipyridamole
therapy attenuated the rise in pulmonary artery pressure and fall in
systemic venous oxygen saturation in all six patients studied with rebound
pulmonary hypertension after withdrawal of inhaled nitric oxide. Conclu-
sion: We conclude that dipyridamole therapy acutely attenuates the adverse
hemodynamic effects of rapid withdrawal of inhaled nitric oxide therapy.
Children with higher pulmonary artery pressure and who are treated with
inhaled nitric oxide for a longer duration may be at increased risk for
adverse hemodynamic effects of inhaled nitric oxide therapy withdrawal.
We speculate that dipyridamole therapy may sustain elevations of smooth
muscle cyclic guanosine monophosphate induced by inhaled nitric oxide
and that phosphodiesterase activity contributes to acute pulmonary hyper-
tension after inhaled nitric oxide withdrawal. (J Thorac Cardiovasc Surg
1998;115:875-82)
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Inhaled nitric oxide (iNO) lowers pulmonary arterypressure (PAP) and pulmonary vascular resistance
(PVR) in many diseases associated with pulmonary
hypertension, including postoperative congenital
heart disease.1-3 Although iNO therapy causes sus-
tained decreases in PVR, iNO therapy may be
complicated by adverse hemodynamic effects after
abrupt withdrawal.4, 5 These effects include in-
creases in PAP and PVR, decreased cardiac output
with a concomitant fall in systemic venous oxygen
saturation (SvO2), decreased systemic arterial pres-
sure (SAP), and decreased arterial oxygenation
(PaO2).
5-7 The occurrence of these adverse hemody-
namic effects after iNO withdrawal is highly variable
among patients and may be transient and resolve
over time6, 8 or be mild and resolve with increases in
inspired oxygen concentrations.5 Other studies have
shown that withdrawal of iNO may cause life-
threatening effects.4 The factors contributing to the
variability in iNO responses or withdrawal effects
remains unknown.
Mechanisms underlying the adverse effects of
sudden iNO withdrawal are unknown but may in-
clude the presence of severe underlying pulmonary
vascular disease with an imbalance of vasodilator
stimuli, such as nitric oxide (NO),9 or increased
production of endogenous vasoconstrictor stimuli,
such as endothelin.10 Other mechanisms may in-
clude down-regulation of endogenous NO produc-
tion.11-13 Recently, persistent or increased degrada-
tion of cyclic guanosine monophosphate (cGMP) by
the cGMP-specific phosphodiesterase enzymes
(PDE5), has been found in animal models of pul-
monary hypertension.14, 15 Because iNO-induced
pulmonary vasodilation is mediated through in-
creased cGMP production in vascular smooth mus-
cle cells, PDE5 inactivation of cGMP may limit the
potency and duration of vasodilation by decreasing
cGMP in smooth muscle cells. Experimental studies
have shown that PDE5 inhibition augments and
prolongs responses to iNO.16-18 Several agents, in-
cluding dipyridamole, zaprinast, and E4021, inhibit
Table I. Clinical characteristics and hemodynamic response to initial inhaled nitric oxide (iNO) withdrawal
Diagnosis Age
mPAP (mm Hg) mSAP (mm Hg) SVO2 (%)
iNO on iNO off iNO on iNO off iNO on iNO off
Rebound (n 5 7)
1. HLH/OCT 3 mo 22 34 86 70 73 61
2. HLH/OCT 4 mo 28 37 75 66 67 56
3. HLH/OCT 4 mo 25 37 63 48 70 60
4. HLH/OCT 5 mo 32 45 78 68 67 42
5. VSD/CoAo 5 mo 32 57 70 68 68 64
6. AS/MS 8 mo 34 62 77 72 73 69
7. TAPVR 12 mo 17 40 76 73 67 62
No rebound (n 5 16)
8. TAPVR 1 day 17 19 65 61 68 70
9. TAPVR 3 days 23 26 83 82 70 70
10. TAPVR 5 days 27 29 70 69 68 67
11. HLH/OCT 1 mo 20 20 65 63 77 77
12. HLH/OCT 1 mo 24 28 76 79 71 73
13. HLH/OCT 1 mo 26 28 66 65 70 67
14. HLH/OCT 1 mo 23 24 59 58 60 58
15. HLH/OCT 1 mo 19 20 64 63 72 73
16. HLH/OCT 2 mo 22 24 75 74 71 70
17. HLH/OCT 2 mo 24 26 80 80 81 82
18. HLH/OCT 3 mo 18 19 81 79 73 74
19. HLH/OCT 3 mo 24 26 62 60 81 78
20. HLH/OCT 3 mo 14 16 83 81 76 73
21. ASD 1 yr 21 24 70 70 74 71
22. CMP/OCT 4 yr 31 33 98 95 64 63
23. CMP/OCT 18 yr 19 21 81 79 72 71
Values are mean 6 SEM; iNO off values 30 minutes after iNO withdrawal. mPAP, Mean pulmonary artery pressure; mSAP, mean systemic artery pressure;
SVO2, systemic venous oxygen saturation; HLH/OCT, hypoplastic left heart syndrome/orthotopic cardiac transplantation; VSD/CoAO, ventricular septal
defect/coarctation of the aorta; AS/MS, aortic stenosis/mitral stenosis; TAPVR, total anomalous pulmonary venous return; ASD, atrial septal defect;
CMP/OCT, cardiomyopathy/orthotopic cardiac transplantation.
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the PDE5 enzymes.14, 18, 19 In human beings, PDE5
inhibitors, such as dipyridamole, may augment the
response to iNO20, 21 and may help in weaning iNO
therapy.22 On the basis of these studies, we hypoth-
esized that PDE5 contributes to the adverse hemo-
dynamic effects after withdrawal of iNO. To test this
hypothesis and to examine potential risk factors for
the variability of this response between patients, we
prospectively studied the effects of iNO withdrawal
in consecutive patients treated with iNO for pulmo-
nary hypertension after surgical repair of congenital
heart disease.
Methods
This protocol was reviewed and approved by the insti-
tutional review board at the University of Colorado
School of Medicine. After obtaining informed consent, we
studied 27 consecutive children (median age: 4.5 months;
range: 1 to 216 months) who were treated with iNO from
July 1, 1995, to July 1, 1997, for pulmonary hypertension
after surgery for congenital heart disease. Four patients
died while receiving iNO therapy and are not included in
this study because iNO could not be withdrawn. All
remaining children in whom iNO was withdrawn were
included in the study. Primary diagnoses of the remaining
23 children included orthotopic cardiac transplantation
for hypoplastic left heart syndrome (14), repair of total
anomalous pulmonary venous return (3), orthotopic car-
diac transplantation for cardiomyopathy (2), revision of
total anomalous pulmonary venous return repair (1),
repair for congenital aortic and mitral stenosis (1), repair
of atrial septal defect with associated bronchopulmonary
dysplasia (1), and repair of ventricular septal defect after
coarctation of the aorta repair and pulmonary artery
banding (1).
Patients were selected for iNO therapy after cardiac
surgery if the mean PAP exceeded 30 mm Hg with
hemodynamic compromise and/or inability to wean from
cardiopulmonary bypass because of clinical signs of right
heart failure. All patients had placement of an Opticath
fiberoptic pulmonary artery catheter (5.5-7.5F; Abbott
Laboratories, North Chicago, Ill.) and a systemic arterial
line for hemodynamic monitoring. iNO therapy was initi-
ated at 20 ppm and administered as previously de-
scribed.23 Methemoglobin, NO and NO2 concentrations
were frequently monitored.23 iNO therapy was weaned by
50% daily, as tolerated based on hemodynamic stability,
and was discontinued when a child’s condition was hemo-
dynamically stable, receiving less than 5 ppm of iNO for 8
hours or more. Hemodynamic stability was defined as a
ratio of mean PAP to SAP of 0.50 or less, adequate gas
exchange (PaCO2 # 40 mm Hg; PaO2 $ 100 mm Hg;
fraction of inspired oxygen # 0.40), and an SvO2 of 60% or
more. After iNO withdrawal, the fraction of inspired
oxygen and ventilator settings remained constant. Study
measurements included PAP, SAP, SvO2, central venous
pressure (CVP), arterial blood gas tensions, and systemic
oxygen saturation (SaO2) for 30 minutes after iNO with-
drawal. Acute pulmonary hypertension (rebound) was de-
fined as a persistent elevation of mean PAP of 20% or
more above baseline with hemodynamic compromise for
more than 30 minutes after iNO withdrawal. We chose a
20% change in mean PAP because many vasoreactivity
studies have used this percentage as an indicator of a
response to vasodilator therapy.3 Children with rebound
pulmonary hypertension were given a trial of dipyridam-
ole therapy. The children were not randomized but rather
given a trial of dipyridamole therapy based on the re-
sponse to withdrawal of iNO. In children with acute
Fig. 1. In the seven children with rebound pulmonary
hypertension after withdrawal of iNO, the ratio of PAP to
systemic artery pressure increased after withdrawal of
iNO in comparison with the 16 patients without rebound.
Table II. Baseline measurements comparing
children with and without rebound pulmonary









iNO dose at withdrawal
(ppm)
3.7 6 0.3 2.8 6 0.5 0.13
iNO treatment (days) 2 6 1 4 6 1 0.01
PAP (mm Hg) 22 6 1 27 6 2 0.04
SAP (mm Hg) 74 6 4 72 6 3 0.55
SvO2 (%) 71 6 2 69 6 1 0.49
PaO2 (mm Hg) 130 6 10 127 6 6 0.86
PaCO2 (mm Hg) 34 6 1 34 6 1 0.93
pH (units) 7.49 6 0.02 7.46 6 0.02 0.24
Values are mean plus or minus standard error of the mean. PAP, Mean
pulmonary artery pressure; SAP, mean systemic artery pressure; SvO2,
systemic venous oxygen saturation.
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pulmonary hypertension, iNO was reinitiated after the
30-minute trial off iNO at the same dose before with-
drawal. In these patients the iNO was given for 30 to 60
minutes with a return of hemodynamic variables to base-
line values. Dipyridamole (0.6 mg/kg) was infused in the
central venous catheter over 20 minutes. The iNO was
again withdrawn, and measurements were obtained after
30 minutes. Patients 1, 2, 3, 4, 6, and 7 received dipyrid-
amole therapy. Patient 5 inadvertently began receiving
calcium channel blockade therapy after the initial three
withdrawals of iNO at the discretion of the attending
physician and therefore did not receive dipyridamole
therapy.
Statistical analysis. All data are expressed as mean 6
standard error of the mean. Confidence intervals (95%
CI) are given where significant differences are found.
Differences between children with rebound and those
without rebound were analyzed by unpaired t test. Differ-
ences during dipyridamole treatment were analyzed by
analysis of variance for repeated measures and Fisher’s
least significant difference test for post hoc comparisons
(Super ANOVA, Berkeley, Calif.).
Results
In nine of the 23 children (39%) iNO was initiated
for difficulty weaning from cardiopulmonary bypass;
the remainder of the children had a PAP that was
greater than 50% of the SAP at the time of initial
iNO treatment. Seven of the 23 children (30%) had
a sustained and significant increase in mean PAP
after iNO withdrawal (Table I). In children without
rebound pulmonary hypertension, hemodynamic
and blood gas variables did not change from treat-
ment values at 30 minutes after iNO withdrawal
(Fig. 1). In comparison with patients without persis-
tent hemodynamic changes after iNO withdrawal,
there were no differences in age, sex, diagnosis, and
use of cardiotonic agents. In children with rebound
pulmonary hypertension, there was a significant
increase in the ratio of mean pulmonary artery to
aortic pressure (Fig. 1; 0.38% 6 0.05%; 95% CI
0.31, 0.45 vs 0.68 6 0.07; 95% CI 0.57, 0.79).
Children with rebound pulmonary hypertension had
a higher ratio of mean pulmonary artery to aortic
pressure than those without rebound pulmonary
hypertension (Fig. 1; 0.38% 6 0.05%; 95% CI 0.31,
0.45 vs 0.31% 6 0.02%; 95% CI 0.28, 0.34). In
addition, the dose of iNO at the time the iNO
therapy was stopped, SAP, CVP, SvO2, PaO2, PaCO2,
pH, or SaO2 were not different between the groups
(Table II). However, immediately before iNO with-
drawal, mean PAP was higher in children with
rebound pulmonary hypertension (Table II; 22 6 1
mm Hg; 95% CI 20, 24 vs 27 6 2 mm Hg; 95% CI
24, 30). Children with acute pulmonary hyperten-
sion after iNO withdrawal had been treated with
iNO for a longer duration than those children in
whom acute pulmonary hypertension did not de-
velop on iNO withdrawal (Table II; 2 6 1 days; 95%
CI 1.9, 2.8 vs 4 6 1 days; 95% CI 3.2, 4.9).
In one child (patient 5), withdrawal of iNO ther-
apy caused significant increases in mean PAP for
over 30 minutes during three consecutive with-
drawal attempts (Fig. 2). In the children with sus-
Fig. 2. Effect of repeated withdrawal of iNO in a patient with pulmonary hypertension (patient 5). This
patient was treated with iNO for 3 days; iNO was withdrawn at 2 ppm. In this patient, iNO withdrawal
caused a sustained and repeatable increase in mean PAP after iNO withdrawal.
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tained pulmonary hypertension after iNO therapy
withdrawal, mean PAP and the ratio of PAP to SAP
increased 40% and 46%, respectively (Figs. 1, 3, and
4). SvO2 fell after iNO withdrawal in these six
patients (Fig. 5; 70% 6 1%; 95% CI 67, 72 vs 58% 6
1%; 95% CI 51, 65). SAP also fell after iNO
withdrawal (p 5 0.01; 74 6 5 mm Hg; 95% CI 66, 81
vs 66 6 4 mm Hg; 95% CI 60, 72). CVP, SaO2, pH,
PaCO2, and PaO2 did not change. Hemodynamic
variables rapidly returned to baseline values on
reinitiation of iNO therapy. Dipyridamole therapy
did not change any hemodynamic or blood gas
variables but attenuated the adverse effects of iNO
withdrawal (Figs. 3, 4, and 5). Dipyridamole therapy
did not change SAP (71 6 5 to 66 6 5 mm Hg; p 5
0.18) but blocked the fall in SAP at iNO withdrawal.
In contrast to the 40% increase in mean PAP (Fig.
3; 26 6 3 mm Hg; 95% CI 22, 30 vs 43 6 4 mm Hg;
95% CI 35, 50) and 46% increase in the ratio of
PAP/SAP without dipyridamole (Fig. 4; 0.36% 6
0.05%; 95% CI 0.28, 0.44 vs 0.65% 6 0.07%; 95%
CI 0.53, 0.77), there was no change in PAP or the
ratio of PAP/SAP after dipyridamole at withdrawal
of iNO (Figs. 3 and 4). Similarly, dipyridamole
therapy attenuated the 17% fall in SvO2 (Fig. 5) and
11% fall in SAP at withdrawal of iNO. Two to three
hours after dipyridamole therapy and withdrawal of
iNO, three of the six children had hemodynamic
instability that necessitated reinitiation of iNO ther-
apy. For patient 5, iNO was withdrawn during
calcium channel blockade. Each patient was subse-
quently weaned from iNO within 24 to 36 hours
without dipyridamole therapy.
Four of the 14 (29%) patients with hypoplastic
left heart syndrome who underwent orthotopic car-
diac transplantation experienced the development
of adverse hemodynamic events after withdrawal of
iNO. All patients with hypoplastic left heart syn-
drome were treated with isoproterenol, dopamine,
and milrinone in addition to iNO. Those patients
with adverse hemodynamic effects were older at the
time of transplantation (p 5 0.01; 4.0 6 0.4 months;
95% CI 3.2, 4.8 vs 1.8 6 0.3 months; 95% CI 1.2,
2.4), were treated with iNO for a longer duration
before withdrawal of iNO (p 5 0.01; 4.8 6 0.3 days;
95% CI 4.3, 5.3 vs 2.7 6 0.3 days; 95% CI 2.1, 3.3),
and had higher mean PAP before withdrawal of iNO
(p 5 0.03; 27 6 2 mm Hg; 95% CI 23, 31 vs 21 6 1
mm Hg; 95% CI 19, 23). The iNO dose at with-
drawal, SAP, SvO2, and blood gas variables were not
different between those children with or without
adverse hemodynamic effects after iNO withdrawal.
Discussion
Since the initial clinical reports of iNO therapy for
persistent pulmonary hypertension of the new-
born,24 adult respiratory distress syndrome,7 and
congenital heart disease,25 it has been recognized
that rapid withdrawal of iNO therapy may cause
marked increases in PAP and decreased oxygen-
ation.4-7 However, other studies8 have shown that
iNO may be withdrawn in patients treated with iNO
for total anomalous pulmonary venous return with-
out adverse events, thus showing the variability in
the response to withdrawal of iNO. To study the
frequency of this response in postoperative congen-
ital heart disease and the potential role of PDE5 in
these acute changes, we studied children treated for
postoperative congenital heart disease. In this pilot
study, 30% (7/23) of children who were treated with
iNO after surgery for congenital heart disease had
acute pulmonary hypertension characterized by a
40% increase in PAP, a 17% decrease in SvO2, and
an 11% decrease in SAP. In comparison with chil-
dren in whom increased PAP did not develop after
iNO withdrawal, patients with acute pulmonary
hypertension had higher mean PAP before iNO was
stopped and were treated with iNO for a longer
Fig. 3. Effects of dipyridamole pretreatment on mean
PAP after withdrawal of iNO (n 5 6). As shown, mean
PAP increased 40% after iNO withdrawal. Reinitiation of
iNO rapidly returned PAP to baseline. Dipyridamole
therapy did not lower PAP during iNO treatment but
attenuated the rise in PAP on repeat withdrawal of iNO.
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duration. Dipyridamole therapy subsequently atten-
uated the adverse hemodynamic effects of iNO
withdrawal in the six patients studied.
Atz and associates8 have shown that after pro-
longed treatment with iNO, PAP increased tran-
siently in all patients when iNO was discontinued. In
this study, the rebound effect was transient and the
peak elevation in mean PAP was observed 7 6 3
minutes after iNO withdrawal. Our results are sim-
ilar in that no patient treated with iNO for the initial
repair of total anomalous pulmonary venous return
had an adverse hemodynamic effect 30 minutes after
the withdrawal of iNO.
Pulmonary hypertension is a risk factor for
children undergoing orthotopic cardiac transplan-
tation.26 Patients with hypoplastic left heart syn-
drome have systemic levels of PAP, elevated left
atrial pressure, and hypoxia. Therefore it is likely
that for some of our patients a sustained elevation
in PAP developed after iNO withdrawal. This is
supported by the fact that rebound pulmonary
hypertension was more common in those patients
with hypoplastic left heart syndrome undergoing
orthotopic cardiac transplantation who were older
at the time of transplantation and had a higher
mean PAP before withdrawal of iNO. In fact,
during the last year only one of 12 patients (8%,
patient 5) has had a rebound effect after with-
drawal of iNO. This likely reflects a change in our
patient population. The eight recent patients with
hypoplastic left heart syndrome were an average
of 1.9 6 0.4 months at the time of transplantation
and did not have a rebound effect after iNO
withdrawal, supporting the theory that younger
patients with hypoplastic left heart syndrome un-
dergoing transplantation are less likely to experi-
ence the development of rebound effects after
withdrawal of iNO. However, patients with hypo-
plastic left heart syndrome and rebound pulmo-
nary hypertension were treated with iNO for a
longer duration before withdrawal of iNO, sug-
gesting that down-regulation of endogenous NO
may play a role.
The purpose of our study was to examine the
potential role of PDE5 in the elevation of PAP after
iNO withdrawal and to determine potential risk
factors for this effect. This pilot study did not
examine whether chronic dipyridamole treatment
would continue to sustain its effects for prolonged
periods. We found that dipyridamole, a cGMP-
specific PDE5 inhibitor, attenuated the adverse he-
modynamic effects after iNO withdrawal in some
patients after surgery for congenital heart disease.
NO causes vasodilation by stimulating cGMP in
vascular smooth muscle. cGMP is hydrolyzed and
inactivated by the PDE5 enzymes. Inhibitors of the
PDE5 enzymes have been shown to lower PVR in
fetal and newborn lambs18, 19 and adult rats with
chronic hypoxia.14 Furthermore, PDE5 inhibitors
augment and prolong the response to iNO in exper-
imental models of pulmonary hypertension.16, 17 In
human beings, PDE5 inhibitors, such as dipyridam-
ole, may augment the response to iNO.20, 21 Al-
though we speculate that the adverse effects of iNO
withdrawal were attenuated by an increase in
cGMP, dipyridamole therapy may prevent the ad-
verse hemodynamic effects as a nonspecific pulmo-
nary vasodilator. Previous studies have shown that
inhibition of hypoxic pulmonary vasoconstriction by
dipyridamole is not due to its platelet-mediated
effects.27 Furthermore, dipyridamole-induced pul-
monary vasodilation in the ovine fetal lung is not
mediated by adenosine,18 and nitric oxide synthase
inhibitors completely block dipyridamole-induced
vasodilation,28 suggesting that the dipyridamole
Fig. 4. Effects of dipyridamole pretreatment on the ratio
of mean PAP to mean systemic artery pressure after iNO
withdrawal (n 5 6). As shown, PAP/SAP initially in-
creased from 35% to 65% after acute iNO withdrawal.
Dipyridamole therapy did not change the pulmonary to
aortic pressure ratio during iNO treatment but attenuated
the rise in pulmonary to aortic pressure ratio after repeat
withdrawal of iNO.
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causes vasodilation primarily through increasing
smooth muscle cGMP.
Marked elevations of PAP with diminished car-
diac output and systemic hypotension have been
described on rapid withdrawal of iNO.4-7 In some
instances, the adverse rebound effects of iNO with-
drawal may be avoided by slow weaning of iNO and
careful attention to adequate oxygenation and he-
modynamic stability. The purpose of our study was
not to determine the efficacy of dipyridamole as a
weaning agent in withdrawal of iNO but rather to
determine risk factors for rebound and the potential
role of PDE5 in rebound. Moreover, rebound effects
of rapid withdrawal of iNO diminish with repeated
attempts to discontinue iNO over time.5 However,
despite adequate blood gas variables, hemodynamic
stability, and sedation during low-dose iNO therapy,
adverse hemodynamic events on discontinuation of
iNO developed in 30% of children with postopera-
tive pulmonary hypertension.
Clinical and laboratory studies have termed the
acute increase in PAP after iNO withdrawal a
rebound phenomenon.6, 11, 13, 29 The mechanisms
responsible for the adverse effects of rapid iNO
withdrawal are unknown. iNO-induced down-regu-
lation of endogenous NO synthase may play an
important role.11, 12 Recent reports suggest that in
hypoxic rats, endogenous NO production is revers-
ibly reduced after short-term NO inhalation and is
likely due to NO synthase inhibition.13 NO donors,
such as nitroglycerin, may be associated with in-
creased superoxide anion production and subse-
quent inhibition of NO-mediated vasodilation, sug-
gesting decreased NO sensitivity.29 However, similar
rebound effects occur in patients with severe pulmo-
nary hypertension after sudden withdrawal of other
vasodilators, such as prostacyclin.30 An imbalance of
vasodilator and vasoconstrictor stimuli may also
contribute to rebound effects. For example, in-
creased production of vasoconstrictors, such as en-
dothelin,10 may augment rebound increases in PAP
after sudden discontinuation of iNO. Thus the re-
bound phenomenon of elevated PAP may not
be exclusively due to decreased endogenous NO
production with iNO therapy. The underlying state
of the pulmonary vasculature may also contribute
to this phenomenon. Our data support the re-
bound phenomenon as being a combination of
diminished endogenous NO production (children
with rebound were treated for a longer duration
than those who did not have rebound) and more
severe pulmonary vascular disease (greater PAP
at the time of iNO withdrawal in children with
rebound).
In summary, children treated with low-dose iNO for
pulmonary hypertension after surgery for congenital
heart disease are at risk for severe pulmonary hyper-
tension after iNO therapy is stopped. Adverse hemo-
dynamic effects of rapid withdrawal of iNO are atten-
uated with dipyridamole therapy. Children treated
with iNO for a longer duration and with a higher mean
PAP at the time of iNO discontinuation may be at
greatest risk for the development of these hemody-
namic effects and may benefit from dipyridamole
therapy before iNO withdrawal. In patients with hyp-
oplastic left heart syndrome treated with orthotopic
cardiac transplantation, patients with adverse hemody-
namic effects were older at the time of transplantation,
were treated with iNO for a longer duration before
withdrawal of iNO, and had a higher mean PAP
before withdrawal of iNO. We speculate that PDE5
activity contributes to rebound pulmonary hyperten-
sion after iNO withdrawal.
We thank Dr. David Campbell, Dr. David Clarke, and
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Fig. 5. Effects of dipyridamole pretreatment on systemic
SvO2 after iNO withdrawal (n 5 6). As shown, SvO2 fell
17% from baseline, suggesting a fall in cardiac output.
Dipyridamole therapy did not change SvO2 but attenuated
the fall in SvO2 after repeat withdrawal of iNO.
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